<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02911870</url>
  </required_header>
  <id_info>
    <org_study_id>NN9924-4247</org_study_id>
    <secondary_id>2015-002418-54</secondary_id>
    <secondary_id>U1111-1170-7054</secondary_id>
    <nct_id>NCT02911870</nct_id>
  </id_info>
  <brief_title>A Thorough QTc Trial Evaluating the Effect of SNAC on Cardiac Repolarisation in Healthy Male Subjects.</brief_title>
  <official_title>A Thorough QTc Trial Evaluating the Effect of SNAC on Cardiac Repolarisation in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to evaluate the effect of SNAC on
      cardiac repolarisation in healthy male subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 23, 2016</start_date>
  <completion_date type="Actual">May 11, 2017</completion_date>
  <primary_completion_date type="Actual">May 4, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment emergent adverse events</measure>
    <time_frame>From dosing (day 1) to follow-up (days 8-11)</time_frame>
    <description>PART A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The co-primary endpoints are Fridericia heart rate corrected QT interval (QTcF)</measure>
    <time_frame>At 10, 20, 30, 40, 50 minutes, 1, 1.5, 2, 2.5, 3, 4, 5, 8, and 12 hours</time_frame>
    <description>PART B</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed SNAC plasma concentration</measure>
    <time_frame>From 0 to 12 hours</time_frame>
    <description>PART A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trial population-specific (accounted for individual subject levels) corrected QT interval (QTcP)</measure>
    <time_frame>At 10, 20, 30, 40, 50 minutes, 1, 1.5, 2, 2.5, 3, 4, 5, 8 and 12 hours</time_frame>
    <description>PART B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the SNAC plasma concentration time curve</measure>
    <time_frame>From 0 to 12 hours</time_frame>
    <description>PART B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed SNAC plasma concentration</measure>
    <time_frame>From 0 to 12 hours</time_frame>
    <description>PART B</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part A, SNAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 1.2mg, 2.4mg or 3.6mg increasing for each cohort of trial participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose at corresponding dose levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, SNAC, Placebo, Moxifloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 4 different treatments in random order. SNAC dose between 1.2-3.6 mg, Placebo in two different periods, moxifloxacin 400mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SNAC</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Part A, SNAC</arm_group_label>
    <arm_group_label>Part B, SNAC, Placebo, Moxifloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Part A, placebo</arm_group_label>
    <arm_group_label>Part B, SNAC, Placebo, Moxifloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Part B, SNAC, Placebo, Moxifloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male aged 18-55 years (both inclusive) at the time of signing informed consent

          -  Body mass index (BMI) between 18.5âˆ’28.0 kg/m^2 (both inclusive)

          -  Considered to be generally healthy based on the medical history, physical examination,
             and the results of vital signs and clinical laboratory tests performed during the
             screening visit, as judged by the investigator

          -  Normal electrocardiogram (ECG) at screening or minor findings considered not
             clinically significant, as judged by the investigator

        Exclusion Criteria:

          -  Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent
             per week), or subject smoking equal to or less than 5 cigarettes or the equivalent per
             week who is not able or willing to refrain from smoking and use of nicotine substitute
             products within 48 hours prior to each dosing and during the in-patient periods

          -  Any blood draw in excess of 25 mL in the past month, or donation of blood or plasma in
             excess of 400 mL within the 3 months preceding screening

          -  Sitting blood pressure at screening (after resting for at least 5 minutes) outside the
             range of 90-139 mmHg for systolic or 50-89 mmHg for diastolic

          -  History of major surgical procedures involving the stomach potentially affecting
             absorption of trial product (e.g. subtotal and total gastrectomy, sleeve
             gastrectomy,gastric bypass surgery)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2016</study_first_submitted>
  <study_first_submitted_qc>September 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2016</study_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

